NCT04184622
SURPASS — tirzepatide in T2D
Phase Phase 3
Status Completed
Indication Type 2 Diabetes
Enrollment 1,879
Last updated:Jul 15, 2026Source:ClinicalTrials.govVerified:NCT ID verified against public registryData provider:ClinicalTrials.gov API v2
Overview
- NCT ID
- NCT04184622
- Phase
- Phase 3
- Status
- Completed
- Indication
- Type 2 Diabetes
- Primary completion
- 2/1/2021
- Enrollment (planned/actual)
- 1,879
- Sponsor
- Eli Lilly
- Peptide
- Tirzepatide
Peptide under study
Tirzepatide
Dual GIP / GLP-1 receptor agonist · Approved